secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2024-10-07T23:59:59+00:00
Accession:  0000950170-24-113210
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma terminates CFO/CBO and COO/CDO; grants retention equity to CEO and VP Finance
--------------------------------------------------------------------------------

- Andrew Gengos (CFO/CBO) and Rachel Lenington (COO/CDO) terminated Oct 1, 2024; severance payments of $363,750 and $375,000 respectively.
- Lenington to provide consulting through Dec 31, 2024 at $41,666.67/month; equity vests during term.
- CEO Mark Litton receives 325k RSUs + 325k options (strike $0.4257); VP Finance Renninger gets 37,077 RSUs + 37,077 options (strike $0.4499).
- Retention awards vest 1/3 each on Dec 31, 2024, Jun 30, 2025, and Dec 31, 2025, subject to continued service.
- 2024 corporate goal achievement percentage automatically increased by 25 percentage points for certain executives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017024113210/0000950170-24-113210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017024113210/atha-20241001.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-113210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer